Gilead Sciences, Inc. (NASDAQ:GILD) on June 15 announced topline results from a Phase 3 clinical trial (GS-US-337-0113) in Japan evaluating the investigational once-daily fixed-dose combination of the NS5A inhibitor ledipasvir (LDV) 90 mg and the nucleotide analog polymerase inhibitor sofosbuvir (SOF) 400 mg, with and without ribavirin (RBV), for the treatment of genotype 1 chronic hepatitis C virus (HCV) infection. Gilead Sciences, Inc. (NASDAQ:GILD) stock … Continue reading Healthcare New Highs: Gilead Sciences (NASDAQ:GILD), Baxter International (NYSE:BAX), WellPoint (NYSE:WLP), The Cooper Companies, Inc. (NYSE:COO), iKang Healthcare (NASDAQ:KANG)